Access and Support | LIVTENCITY® (maribavir)

Access & Support

OUTPATIENT USE
INPATIENT USE

3 Ways to enroll in Takeda Patient Support

Choose one of the convenient options below to complete the LIVTENCITY Start Form.

Fax

Download and complete the Start Form. Then fax the completed form to Takeda Patient Support at 1-855-268-1826.

DOWNLOAD FORM

Online

Visit our easy-to-use online enrollment. In a few clicks, your patient can be enrolled in Takeda Patient Support

iAssist

Enroll your patients in Takeda Patient Support with this easy-to-use registration.

Takeda Patient Support will review the Start Form and confirm patient eligibility.

Once eligibility requirements have been confirmed, the specialty pharmacy will coordinate the shipment of LIVTENCITY with the patient.

Important information

Your patients do not need to be present when completing the Start Form.
Please direct your patients to provide their consent by texting YES to 1-844-972-4268 after you have submitted the Start Form.

Takeda Patient Support

Benefits investigation

We provide support during the process of determining a patient’s insurance benefits and eligibility for certain services.

Prior authorization information

We’ll coordinate with your patient’s insurance company to determine any prior authorization requirements.

Specialty pharmacy triage and coordination

Through the selected pharmacy options, we’ll work with your patient’s insurance provider to help them gain access to LIVTENCITY.

Financial assistance options

Our Patient Support Managers (PSMs) can help educate patients on financial assistance options, if eligible.

Product and disease state education

Trained nursing professionals are ready to provide your patient education on their condition and LIVTENCITY. They cannot provide medical advice.

LIVTENCITY may be purchased directly by qualified
entities* from the following distributor

Cardinal Health Specialty

Phone: 1-866-677-4844

*Qualified entities for direct purchase include inpatient hospitals properly licensed by regulatory
authorities to administer or dispense pharmaceutical products to appropriate patients, entities
eligible to purchase under the Federal Supply Schedule, and 340B covered entities.

SEE THE SAFETY PROFILE

IMPORTANT SAFETY INFORMATION

Risk of Reduced Antiviral Activity When Co-administered with Ganciclovir and Valganciclovir

LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of ganciclovir and valganciclovir. Coadministration of LIVTENCITY with ganciclovir or valganciclovir is not recommended.

Virologic Failure During Treatment and Relapse Post-Treatment

Virologic failure due to resistance can occur during and after treatment with LIVTENCITY. Virologic relapse during the posttreatment period usually occurred within 4-8 weeks after treatment discontinuation. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. Monitor CMV DNA levels and check for maribavir resistance if the patient is not responding to treatment or relapses.

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. Consider the potential for drug interactions prior to and during LIVTENCITY therapy; review concomitant medications during LIVTENCITY therapy and monitor for adverse reactions. Refer to the full prescribing information of LIVTENCITY for important drug interactions.

Maribavir is primarily metabolized by CYP3A4. Drugs that are strong inducers of CYP3A4 are expected to decrease maribavir plasma concentrations and may result in reduced virologic response; therefore, coadministration of LIVTENCITY with these drugs is not recommended, except for selected anticonvulsants.

Use with Immunosuppressant Drugs

LIVTENCITY has the potential to increase the drug concentrations of immunosuppressant drugs that are CYP3A and/or P-gp substrates where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus). Frequently monitor immunosuppressant drug levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust immunosuppressant dose, as needed.

Adverse Reactions

The most common adverse events (all grades,> 10%) in subjects treated with LIVTENCITY were taste disturbance, nausea, diarrhea, vomiting, and fatigue.

INDICATION

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Please click for Full Prescribing Information.